Every year, the IMI Stakeholder Forum gathers IMI’s stakeholders in health and medicines R&D and provides them with an opportunity to learn about and discuss IMI’s latest activities and plans.
The IMI Stakeholder Forum will open its doors on Wednesday 28 September at 13:00, and draw to a close on Thursday 29 September at 17:00.
IMI Stakeholder Forum 2016: Wednesday 28 September
Download the agenda of day 1 of the IMI Stakeholder Forum.
Raju Kucherlapati, Paul C. Cabot Professor of Genetics and Professor of Medicine at the Harvard Medical School, will provide the keynote lecture.
IMI Scientific Officers will present the topics of IMI’s upcoming 10th Call for proposals, followed by a networking cocktail and dinner where participants will have the opportunity to meet IMI staff and network with potential partners around the topics of Call 10.
The IMI legal team will provide a presentation on the IMI Intellectual Property rules.
A panel including IMI project participants, SMEs and IMI Associated Partners will debate the advantages for participating in an IMI project and discuss advice for applicants with Hugh Laverty, IMI’s Head of Scientific Operarions.
IMI Stakeholder Forum 2016: Thursday 29 September
The second day will be dedicate to parallel consultative workshops on strategic research areas, bringing together IMI stakeholders to shape the future of IMI’s programme. The four parallel consultations will cover advanced therapies, biopreparedness, digital health and oncology.
New treatment approaches for diseases with high-unmet medical need include medicinal products based on genetic engineering, innovative cell-based therapies and tissue-engineered products. In the EU, these new therapies are commonly known as advanced therapy medicinal products (ATMPs). There are numerous factors that have complicated the translation from research into patient access. IMI, in collaboration with key stakeholders, has run consultation exercises on advanced therapies with the goal to identify the potential of IMI as a platform for enhancing ATMP research and development. The goal of this workshop is to assess the input collected in previous consultations, and draw conclusions to inform the development of an IMI ATMP portfolio of projects that could be launched from 2017 onwards.
Georg Terstappen, Director and Head of Biology, AbbVie;
Alain Fischer, Hôpital Necker, Paris
Mimoun Azzouz, Director of Research & Innovation Department of Neuroscience, University of Sheffield;
Eduardo Bravo, TiGenix;
Chris Sotirelis, UK Thalassaemia Society;
Carole Longson, NICE.
Find out about the pre-event consultation.
Recent epidemics of existing and new diseases have emerged in different regions of the world, including not only the Ebola and Zika viruses, but also the Dengue fever in Southern Europe and the Yellow fever outbreak in Angola. The patterns of these phenomena are linked to a complex variety of factors, including climate change trends, vaccine supplies and uptake, and geopolitical challenges. A number of organisations have a role to play in tackling such public health emergencies. IMI is among these. But while programmes like IMI cannot fully respond to all of these issues, a public-private partnership could offer the advantages, flexibility and complementary assets to make a difference. The goal of this consultative workshop is to gather input from stakeholders involved in public health emergencies in order to ascertain whether a public-private supported platform could play a role, and if so – how, in selecting rapid approaches to treatment and intervention options. This consultation workshop is jointly organised by IMI, the European Commission and EFPIA. Confirmed speakers:
Herman Goossens, Professor of Microbiology, University of Antwerp;
Line Matthiessen, Head of Unit, Fighting infectious diseases and advancing public health, DG Research & Innovation, European Commission;
Marie-Paule Kieny, Assistant Director-General – Health Systems and Innovation, World Health Organization (WHO);
John-Arne Røttingen, CEPI – Coalition for Epidemic Preparedness Innovations, c/o Norwegian Institute of Public Health;
Piotr Kramarz, Deputy Chief Scientist, European Centre for Disease Prevention and Control (ECDC)
Jean Lang, Associate Vice President, Sanofi Pasteur;
Michael Makanga, Executive Director, European & Developing Countries Clinical Trials Partnership (EDCTP);
Mark Miller, Chief Medical Officer, BioMerieux;
Philippe Denoel, Director, External R&D at GlaxoSmithKline Biologicals.
IMI has been focusing on digital health through its RADAR-CNS and WEB-RADR projects. This workshop aims to review what IMI has done in the digital area; what other partnerships such as the ECSEL Joint Undertaking are working on; discuss the use of digital technologies in medicines R&D; identify what patients, doctors, regulators, payers and HTA bodies expect from digital technologies; and assess what IMI could do to bridge any gaps in digital health research. Discussions will also address the question of data ownership, access and use. Confirmed speakers:
Matthew Hotopf, NIHR Maudsley Biomedical Research Centre, RADAR-CNS;
Bert de Colvenaar, ECSEL Joint Undertaking;
Nabarun Dasgupta, Epidemico, IMI WEB-RADR project.
This workshop is organised with the IMI Strategic Governing Group (SGG) Oncology, in order to better understand the current gaps in oncology research; to assess whether an IMI project would be considered the appropriate tool to address any of these gaps; to discuss, if an IMI Call was to focus on this topic, what would be the most appropriate and effective Call process and project strategies. Confirmed speakers:
Stefan J. Scherer, Vice-President Global Head Correlative Science, Novartis; Chair of the IMI Strategic Governing Group (SGG) Oncology;
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer (EORTC);
Françoise Meunier, Director Special Projects, European Organisation for Research and Treatment of Cancer (EORTC);
Alexander Eggermont, General Director, Gustave Roussy:
David Cameron, Chair of Oncology/Head of Cancer Services, School of Molecular, Genetic and Population Health Sciences, University of Edinburgh;
Jan Geissler, Director of EUPATI, the European Patients Academy on Therapeutic Innovation;
Raju Kucherlapati, Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
Registration is free but obligatory. To register, fill in this form.
Who should attend? which stakeholders?
All stakeholders in health and medicines research and drug development are welcome: policy makers, academia, pharmaceutical industry and other sectors in healthcare, SMEs and mid-sized enterprises,patient representatives and regulators, representatives of other public-private partnerships andresearch funding organisations.